John W. Campbell III

John W. Campbell III

Senior Counsel

San Francisco, (415) 268-7197

Education

Duke University (A.B., 1979)
Yale Law School (J.D., 1982)

Bar Admissions

California

John Campbellhas practiced in San Francisco and Silicon Valley for over 35 years. He has extensive experience as corporate counsel to offshore and U.S. public and private companies, and the venture capital firms and financial intermediaries that provide financing to them. He has represented companies and investors in over 300 venture capital and debt financing transactions, dozens of public offerings and numerous public and private M&A transactions.

John counsels companies at all stages in their life cycles. He distinguishes himself by achieving successful outcomes for clients through pragmatic, results-oriented analysis and creative, strategic thinking. He has been instrumental in starting, building and exiting numerous emerging growth companies in the life sciences and technology industries, including biotechnology, specialty pharmaceuticals, diagnostics and laboratory equipment, and semiconductors, telecommunications, software, e-commerce and social networking.

John has served as lead counsel on countless mergers and acquisitions including public company mergers, tender offers and spin-offs, ranging in size from $3 million to over $40 billion. He regularly advises management teams, special committees and boards of directors in acquisition and restructuring situations which present complex structural and governance challenges.

John has advised on dozens of capital markets transactions, including more than 30 initial public offerings and numerous public and private offerings of debt and equity securities in 144A, PIPE and similar structured transactions.

John has served as general counsel and advised on 1934 Act compliance and corporate governance matters for a substantial number of public companies, including foreign private issuers.

John is a past co-chair of Morrison & Foerster’s Life Science Group and the firm’s Emerging Company and Venture Group. He also served as a member of the supervisory board of a European and U.S. focused venture capital firm with an invested portfolio of over $250 million.

John graduated summa cum laude with distinction in economics from Duke University, was a member of Phi Beta Kappa, and served as a member of the Yale Law Journal.

InvenSense’s acquisition of the microphone business of Analog Devices.
Represented InvenSense, Inc. (NYSE:INVN), the leading provider of fully integrated motion processing solutions for mobile and consumer applications, in its acquisition of the microphone business of Analog Devices Incorporated.


Textainer’s IPO.
Represented Textainer Group Holdings, the world’s leading lessor of marine intermodal shipping containers, in its $150 million initial public offering.


Textainer’s Acquisitions of Capital Leasing and Amphicon.
Represented Textainer in its acquisitions of the marine container fleets of Capital Leasing and Amphicon International.


Westaff’s Acquisition by Select Staffing.
Represented Westaff, Inc. in its acquisition for cash and debt totaling $66 million by Select Staffing, Inc.


Wafergen Financings.
Represented Wafergen Bio-Systems, Inc. in registered direct and PIPE financing transactions as well as in financings effected through a special purpose R&D subsidiary formed to raise capital and conduct research in Malaysia.


CastTV’s acquisition by Tribune Company.
Represented CastTV, Inc., in its acquisition by Tribune Media Services, a subsidiary of the Tribune Company.


Aradigm Financings.
Represented Aradigm, Inc. in PIPE transaction and retirement of debt through a sale of equity to Novo Nordisk.


BetaWave Financings.
Represented Betawave in $25 million preferred stock PIPE transaction, $10 million convertible debt PIPE transaction, and several other financings.


Astellas’s acquisition of Agensys and product rights from Fibrogen.
Represented Astellas Pharma Inc., Japan's second-largest drug maker, in its $537 million acquisition of Agensys Inc., and its acquisition of rest of world rights to certain products being developed by FibroGen Inc. for $815 million.


Century Theatre’s acquisition by Cinemark.
Represented Century Theatres, Inc., and its parent Syufy Enterprises in its sale to Cinemark, Inc. and its private equity sponsor Madison Dearborn for $1.05 billion.


InvenSense Financings.
Represented InvenSense, the leading provider of fully integrated motion processing solutions for mobile and consumer applications, in raising $40 million in a series of venture capital financings.


Integrated Flow Systems acquisition by AIT.
Represented Integrated Flow Systems, LLC in its acquisition by Advanced Integrated Technologies and its private equity sponsor Sunrise Partners.


InvenSense IPO.
Represented InvenSense in $83 million initial public offering underwritten by Goldman Sachs and Morgan Stanley.


InvenSense follow-on offering.
Represented InvenSense in $111 million follow-on offering underwritten by Goldman Sachs and Morgan Stanley.


TOUT financings.
Represented Tout Industries, a leading social media video networking company, in its spin-out from SRI and Series A financing.


Epitomics financings.
Represented Epitomics, Inc., developer of monoclonal antibodies, in five rounds of venture financing and pending initial public offering in Taiwan.


Epitomics’ acquisition by Abcam PLC.
Represented Epitomics International, a leading manufacturer of monoclonal antibodies for biomedical and in-vitro diagnostic research, in its $170 million cash and stock acquisition by Abcam PLC


Telome Health financing.
Represented Telome Health and its founders in licensing of technology from UCSF and financing.


Leapfrog offering.
Represented Leapfrog Enterprises in shelf registration for secondary offering of securities.


Mr. Campbell is recommended as a leading lawyer by Legal 500 US 2018, Chambers USA 2008–2015, Best Lawyers In America 2007–2020 and Super Lawyers 2004–2013 and 2015–2018.

MoFo ScaleUp

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.